Loading
AI
Augmedix, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 27 Nov 2023.
Augmedix, Inc.: what insiders have been doing
Augmedix, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for Augmedix, Inc. The previous disclosure was published on 4 October 2024.
Our records for Augmedix, Inc. go back to 2021, with 21 purchases and 14 sales on the open market in total.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
94
Thresholds
n/a
Buy Volume
€11M
21 ops. · all time
Sell Volume
€3M
14 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$38.6M
Gross profitUS$18.5M48% margin
Net income-US$16.5M-42.7% margin
Last declaration on 4 October 2024
Declarations94 total
16,421,788 shares@ US$2.3565.7% of flowCommon StockSEC:0001104659-24-106315:0
74,230 shares@ US$2.35100.0% of flowCommon StockSEC:0001213900-24-085351:0
21,598 shares@ US$2.35100.0% of flowCommon StockSEC:0001213900-24-085362:0
41,461 shares@ US$2.3590.5% of flowCommon StockSEC:0001104659-24-106311:0
124,126.75 shares@ US$2.3566.1% of flowCommon StockSEC:0001213900-24-085353:0
135,795 shares@ US$2.3581.7% of flowCommon StockSEC:0001213900-24-085356:0
7,701 shares@ US$2.352.2% of flowCommon StockSEC:0001213900-24-085345:0
5,844 shares@ US$2.35100.0% of flowCommon StockSEC:0001213900-24-085370:0
20,295 shares@ US$2.35100.0% of flowCommon StockSEC:0001213900-24-085366:0
74,230 shares@ US$2.35100.0% of flowCommon StockSEC:0001213900-24-085349:0
5,844 shares@ US$2.35100.0% of flowCommon StockSEC:0001213900-24-085346:0
162,583 shares@ US$2.35100.0% of flowCommon StockSEC:0001213900-24-085379:0
64,748 shares@ US$2.35100.0% of flowCommon StockSEC:0001213900-24-085342:0
6,250 sharesCommon StockSEC:0001213900-24-070867:0
3,750 sharesCommon StockSEC:0001213900-24-070870:0
6,250 sharesCommon StockSEC:0001213900-24-070865:0
4,687 sharesCommon StockSEC:0001213900-24-070863:0
9,375 sharesCommon StockSEC:0001213900-24-070862:0
4,687 sharesCommon StockSEC:0001213900-24-070868:0
3,750 sharesCommon StockSEC:0001213900-24-070875:0
1,322 shares0Common StockSEC:0001013762-24-002827:0
21,598 sharesCommon StockSEC:0001213900-24-061516:0
21,598 sharesCommon StockSEC:0001213900-24-061519:0
21,598 sharesCommon StockSEC:0001213900-24-061517:0
21,598 sharesCommon StockSEC:0001213900-24-061515:0
25 of 94 declarations
About Augmedix, Inc.
Competitively, Augmedix operated in a highly contested healthcare IT niche, facing pressure from larger EHR vendors, outsourced documentation providers, and newer ambient-scribing AI platforms. Its differentiation was based on a mix of software, service delivery, and workflow integration, particularly for enterprise health systems. A major recent milestone was the July 2024 announcement of a definitive agreement to be acquired by Commure in an all-cash transaction valued at roughly $139 million, followed by closing in October 2024 and the subsequent delisting of Augmedix shares from the NASDAQ. For French-speaking investors, Augmedix is best viewed as a U.S. digital health case study marked by rapid sector consolidation rather than a still-listed standalone equity story.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
